Two Months Left to Submit Program Year 2021 Attestations; Security Risk Analysis
Blog Entry List
Will cover all U.S. FDA approved CAR T-Cell Therapies when administered per U.S. FDA approved guidelines
Temporary Suspension of Prior Authorization for Post-Acute Placements and Temporary Availability of the Hospital at Home Program
This replaces the bulletin, published on Aug. 4, 2021
Casirivimab and Imdevimab have been given emergency use authorization for treatment of mild to moderate COVID-19 in some patients.
Billing codes for Medicaid beneficiaries
Tips for providers to reduce the likelihood of future documentation errors
Providers rendering personal care services subject to EVV through the prepaid health plan payer type have until Oct. 1, 2021 to complete EVV credentialing and begin processing EVV claims.
To support providers during the recent COVID-19 surge, the policy for in-network provider provisions has been extended
PHPs are required to provide drug coverage to Medicaid beneficiaries consistent with the drug coverage determined by NC Medicaid under fee for service.
Taxonomy codes must be included when submitting claims to prepaid health plans
Ensure compliance with the HCBS final rule and prepare Tailored Plans and Providers for the launch of Tailored Care Management.
Effective with date of service June 28, 2021, the Medicaid and NC Health Choice programs cover dasiglucagon injection, for subcutaneous use (Zegalogue®)
Effective with date of service July 1, 2021, the Medicaid and NC Health Choice cover bupivacaine and meloxicam extended-release solution.